Minnesota Court Interprets Scope of Estoppel for CBM Review

Mar 19, 2018

Reading Time : 1 min

Back in district court after the failed CBM review, Bancorp asserted another obviousness defense based on a different patent application (Randle ’717), a sibling application to the Randle ’283 application asserted in the PTAB.  Solutran filed a motion in limine, arguing that Bancorp was estopped from asserting obviousness arguments in district court.  Solutran’s estoppel argument was rooted in the estoppel provision of the CBM review statute, which provides that the petitioner in the CBM review “may not assert . . . in a civil action arising in whole or in part under section 1338 of title 28, United States Code . . . that the claim was invalid on any ground that the petitioner raised during [the CBM review].”  See Pub. L. 112-27, § 18(a)(1)(D), 125 Stat. 330 (2011).  Solutran contended that the word “ground” in the statute was not limited to the specific obviousness arguments asserted in the CBM review.  Judge Nelson denied the motion, holding that “the word ‘ground’ in the CBM estoppel provision refers to a discrete claim of invalidity based upon a prior art or combination of prior art.”

Solutran filed a related motion in limine, arguing that Bancorp was estopped from introducing the Randle ’717 reference due to its similarity to the Randle ’283 reference from the failed CBM review.  In opposition, Bancorp argued that estoppel bars obviousness arguments based only  on the same set of limitations from the same combination of prior art.  Finding merit in Solutran’s argument, Judge Nelson stated that, if “Randle ’717 does not provide any new disclosures or features that Defendants could not have argued from Randle ’283, then it will be estopped.”  The court deferred the issue and invited Bancorp to attempt to distinguish Randle ’717 from Randle ’283.

Thus, according to the order, parties cannot avoid CBM estoppel by simply relying on related prior art with the same disclosure as that asserted before the PTAB; rather, the prior art asserted in district court must disclose limitations that were not disclosed in the related prior art asserted at the PTAB.

Solutran, Inc. v. U.S. Bancorp, Inc., No. 0:13-cv-02637-SRN-BRT (D. Minn. Mar. 3, 2018)

Share This Insight

Categories

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.